

1. PATIENT INFORMATION		
FIRST NAME	LAST NAME	PATIENT MRN
DOB (MM/DD/YYYY)	RACE/ETHNICITY	SEX <input type="checkbox"/> M <input type="checkbox"/> F
STREET ADDRESS	CITY & STATE	COUNTRY
POSTAL CODE	PHONE	EMAIL

2. TREATING PHYSICIAN INFORMATION		
FIRST NAME	LAST NAME	NPI
MEDICAL CENTER		
STREET ADDRESS	CITY & STATE	COUNTRY
POSTAL CODE	PHONE & FAX	EMAIL

3. BILLING INFORMATION (PLEASE SELECT 3A, 3B OR 3C)				
BILL TYPE	<input type="checkbox"/> 3a. INSURANCE (PLEASE ATTACH THE FRONT AND BACK COPIES OF THE INSURANCE CARD)			
	<input type="checkbox"/> COMMERCIAL INSURANCE	POLICY NUMBER	POLICY HOLDER NAME	POLICY HOLDER DOB (MM/DD/YYYY)
	<input type="checkbox"/> MEDICARE	GROUP NUMBER	PRIOR AUTHORIZATION NUMBER	
	PATIENT STATUS AT TIME OF COLLECTION <input type="checkbox"/> NON-HOSPITAL/OFFICE <input type="checkbox"/> HOSPITAL INPATIENT - DATE OF DISCHARGE (MM/DD/YYYY)		<input type="checkbox"/> HOSPITAL INPATIENT - NOT DISCHARGED	
	<b>(REQUIRED FOR ALL MEDICARE PATIENTS)</b> <input type="checkbox"/> OUTPATIENT			
<input type="checkbox"/> 3b. FACILITY				
STREET ADDRESS		<input type="checkbox"/> SAME AS TREATING PHYSICIAN		
<input type="checkbox"/> 3c. SELF-PAY				
CONTACT NAME		PHONE	EMAIL	

4. CLINICAL INFORMATION (PLEASE ATTACH THE PHYSICIAN NOTE OR CLINICAL HISTORY SUMMARY)			
DIAGNOSIS		STAGE	ICD-10 CODE
CANCER TYPE	<input type="checkbox"/> LUNG <input type="checkbox"/> BREAST <input type="checkbox"/> PROSTATE <input type="checkbox"/> COLORECTAL <input type="checkbox"/> MELANOMA <input type="checkbox"/> KIDNEY <input type="checkbox"/> OVARIAN <input type="checkbox"/> DLBCL/FL <input type="checkbox"/> OTHER _____	PATIENT RECEIVED TRANSPLANT <input type="checkbox"/> NO <input type="checkbox"/> YES _____	
DISEASE STATUS	<input type="checkbox"/> RECURRENT <input type="checkbox"/> RELAPSED <input type="checkbox"/> REFRACTORY <input type="checkbox"/> ADVANCED (STAGES III/IV) <input type="checkbox"/> METASTATIC <input type="checkbox"/> OTHER _____	CURRENT LINE OF THERAPY	
HAS THE PATIENT BEEN PREVIOUSLY TESTED WITH ANOTHER CGP TEST FOR THE SAME CANCER GENETIC CONTENT (E.G., CARIS MI PROFILE™, TEMPUS xT 648, FM1 CDx ETC.)?			<input type="checkbox"/> YES <input type="checkbox"/> NO
SPECIAL NOTE IF A PHYSICIAN NOTE OR A CLINICAL HISTORY SUMMARY IS NOT PROVIDED SEPARATELY, YOU MAY BE CONTACTED IN ORDER TO COMPLETE THE DETAILED CLINICAL INFORMATION FORM.			

5. SPECIMEN INFORMATION (PLEASE ATTACH THE PATHOLOGY REPORT)			
5a. TUMOR SPECIMEN			
SPECIMEN TYPE	<input type="checkbox"/> FFPE TISSUE (INC. BONE MARROW) <input type="checkbox"/> FRESH TISSUE	ACQUISITION METHOD	<input type="checkbox"/> BIOPSY <input type="checkbox"/> SURGICAL
SPECIMEN SITE	<input type="checkbox"/> PRIMARY TUMOR <input type="checkbox"/> NOT APPLICABLE <input type="checkbox"/> METASTATIC	SITE _____	
5b. NORMAL SPECIMEN			
SPECIMEN TYPE	<input type="checkbox"/> SALIVA <input type="checkbox"/> BLOOD (NOT ACCEPTED IN CASE OF HEME CANCERS <sup>2</sup> ) <input type="checkbox"/> FF/FFPE SKIN BIOPSY	DATE OF COLLECTION (MM/DD/YYYY)	SEND TO PATIENT <input type="checkbox"/> MOBILE PHLEBOTOMY <input type="checkbox"/> SALIVA KIT

6. FFPE SPECIMEN RETRIEVAL		
PATHOLOGY LAB NAME	<input type="checkbox"/> SPECIFIC SPECIMEN REQUESTED	
FFPE RETURN <input type="checkbox"/> YES	<input type="checkbox"/> SUBMITTING PATHOLOGIST WILL CHOOSE A SPECIMEN	
CASE NUMBER	BLOCK NUMBER	BIOPSY DATE (PERFORMED OR SCHEDULED FOR) (MM/DD/YYYY)

7. TREATING PHYSICIAN SIGNATURE		
By signing this form, I affirm that this test is medically necessary and that I am authorized to order this test. I also confirm that the patient's written consent has been obtained (a) to perform the test; (b) to release accompanying medical information to BostonGene; (c) to remit test results to patient's payer for reimbursement; and (d) to assign the patient's right to payment for services provided by BostonGene and for BostonGene to pursue any and all necessary appeals of full or partial payment on behalf of the patient.		
PHYSICIAN SIGNATURE	PRINTED NAME	DATE (MM/DD/YYYY)

8. FORM COMPLETED BY		
FULL NAME	PHONE	EMAIL

9. ADDITIONAL PHYSICIAN TO BE COPIED (OPTIONAL)		
FULL NAME	PHONE	EMAIL

10. SAMPLE REQUIREMENTS	
10a. GENERAL REQUIREMENTS	
FRESH TISSUE	30-100 MG COLLECTED IN THE PROVIDED CRYOGENIC TUBES. SHIP OVERNIGHT WITH ROOM TEMPERATURE GEL REFRIGERANT VIA FEDEX.
WHOLE BLOOD	5-10 ML IN THE PROVIDED EDTA BLOOD COLLECTION TUBE. SHIP OVERNIGHT WITH ROOM TEMPERATURE GEL REFRIGERANT VIA FEDEX.
FFPE	1 FFPE BLOCK NOT OLDER THAN 6 YEARS OLD (IDEALLY THE MOST RECENT) OR 10 UNSTAINED SLIDES (5 MICRONS) WITH 1 H&E SLIDE. SHIP VIA FEDEX.
<sup>1</sup> FFPE BONE MARROW	WE ACCEPT BONE MARROW SAMPLES DECALCIFIED IN EDTA.
SALIVA	COLLECT ABOUT 2 ML OF SALIVA USING THE PROVIDED SALIVA KIT. PATIENT SHOULD NOT EAT, DRINK, SMOKE OR CHEW GUM BEFORE GIVING SAMPLE. SHIP OVERNIGHT VIA FEDEX.
10b. SPECIAL CASES	
BLOOD TRANSFUSION	BLOOD AS A "NORMAL" SAMPLE IS NOT ACCEPTABLE IF A PATIENT HAS UNDERGONE A BLOOD TRANSFUSION. IN THIS CASE, SALIVA IS RECOMMENDED AS A NORMAL SAMPLE.
BONE MARROW TRANSPLANT	BLOOD AND SALIVA ARE NOT ACCEPTABLE IF A PATIENT HAS UNDERGONE A BONE MARROW TRANSPLANT. IN THIS CASE A SKIN BIOPSY IS RECOMMENDED AS A NORMAL SAMPLE.
<sup>2</sup> HEME CANCERS	BLOOD AS A "NORMAL" SAMPLE IS NOT ACCEPTABLE IN CASE OF HEME CANCERS. IN THIS CASE, SALIVA IS RECOMMENDED AS A NORMAL SAMPLE.

11. CHECKLIST	
REQUIRED SUPPORTING DOCUMENTS: <input type="checkbox"/> FRONT/BACK COPY OF INSURANCE CARD <input type="checkbox"/> TREATING PHYSICIAN PROGRESS NOTE <input type="checkbox"/> RELEVANT LAB RESULTS <input type="checkbox"/> PATHOLOGY/CYTOLOGY REPORT	ADDITIONAL DOCUMENTS - OPTIONAL: <input type="checkbox"/> RADIOLOGY REPORTS, RADIATION THERAPY NOTES, DICOM IMAGES <input type="checkbox"/> RADIOLOGY/OPERATIVE REPORTS <input type="checkbox"/> PRIOR MOLECULAR TEST REPORTS <input type="checkbox"/> HISTORICAL PROGRESS REPORTS <input type="checkbox"/> BOSTONGENE FINANCIAL ASSISTANCE PROGRAM APPLICATION FORM

**CONSENT TO DISCLOSURE OF GENETIC AND RELATED MEDICAL INFORMATION AND TISSUE SPECIMENS TO BOSTONGENE FOR THE PERFORMANCE OF BOSTONGENE TUMOR PORTRAIT™ TEST**

The BostonGene Tumor Portrait™ Test uses whole-exome sequencing (WES) and transcriptome sequencing (RNA sequencing or RNAseq) to detect genomic alterations such as single nucleotide variants (SNV), insertions/deletions (indels), copy number alterations (CNA), tumor mutational burden (TMB), microsatellite instability (MSI), fusions, frameshifts, rearrangements and expression levels of more than 20,000 genes. BostonGene-integrated genomic and transcriptomic analysis, in concert with the patient's medical history, provides information regarding the likely benefits of therapies or therapeutic combinations, suitable NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) treatment recommendations and ongoing clinical trials.

The process of DNA and RNA sequencing is not 100% error free. The analysis of nucleic acids by next-generation sequencing (NGS) can be affected by multiple factors and may be influenced by specimen collection and storage processes. The lack of detection of a genomic alteration does not definitively rule out that the patient does not carry this genomic variation. Detection of an alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any therapeutic or therapeutic regimen. The BostonGene Tumor Portrait™ Test is a CLIA certified Laboratory Developed Test (LDT) that is not subject to review by the FDA and does not make any definitive treatment recommendations. Decisions regarding your care and treatment, including selection of therapies, are solely based on the independent medical judgment of your doctor. If you have any questions or need additional information, please consult your doctor before signing.

By signing below you consent to the transfer of your tissue samples and the disclosure of your protected health information ("PHI") for treatment purposes to BostonGene for BostonGene Tumor Portrait™ testing. Submitting your sample for testing is voluntary and you may choose not to have your sample tested. Your personal information will be stored and protected in compliance with applicable U.S. and state laws. There are state and federal laws that prohibit discrimination against individuals for the purpose of employment or obtaining health insurance, and prohibit insurers and employers from seeking an individual's genetic information without consent. However, it is your responsibility to consider the possible impact of genetic test results as they relate to insurance rates and obtaining disability or life insurance and employment. The federal Genetic Information Nondiscrimination Act (GINA) provides some protections against genetic discrimination.

**USE AND RETENTION OF DE-IDENTIFIED LEFTOVER SPECIMENS RESULTS, AND CLINICAL INFORMATION FOR RESEARCH PURPOSES <sup>3</sup>**

BostonGene may remove personally-identifiable information from your tissue samples, results, and clinical information in accordance with applicable law and use and store it indefinitely for de-identified research and development purposes. Although the results of research involving your de-identified sample and clinical information may be patentable or have commercial value, you will have no legal or financial interest in any commercial development resulting from the research. You may withdraw your consent to use your specimens, results and information for research purposes and/or request the destruction of your specimens or deletion of your information at any time, with the understanding that, to the extent such sample or information has already been de-identified or used, it cannot be destroyed or retrieved. You may request destruction of your specimens or deletion of your information by sending an email to [clientservices@bostongene.com](mailto:clientservices@bostongene.com). If you do not want to allow your de-identified sample or information to be used or stored for research, please check the box at the bottom of this form. Checking the box will not adversely affect your medical care or results.

**GENOMIC SEQUENCING SECONDARY FINDINGS <sup>4</sup>**

The use of your genomic information may reveal one or more findings not related to the reason for the test known as secondary findings. Many secondary findings are not related to cancer. BostonGene will not report secondary findings not related to cancer if you opt-out and check the box below. If you consent, you may receive information beneficial to you or your family, although you may also receive information regarding your or your family's risk for certain diseases and conditions. Some secondary findings are related to cancer. BostonGene will therefore provide secondary findings related to cancer even if you do not opt-in and consent to receive secondary findings because they may describe your or your family's risk for certain cancers and may be beneficial for you and your family. BostonGene strongly recommends that you receive additional consultation from your doctor or a genetic counselor regarding any secondary results you receive because secondary results are not related to the reason that the ordering physician authorized this test. For a list of medical geneticists and counselors who may be available in your area, please visit the National Society of Genetic Counselors website at [nsgc.org](http://nsgc.org).

**FUTURE CONTACT <sup>5</sup>**

Your healthcare provider or BostonGene may also contact you regarding ongoing research, including findings specific to your disease or genomic data, as well as to obtain information regarding your future medical care.

**PATIENT CONSENT**

By signing below\* you confirm that you have read this consent form, that your physician has reviewed with you the purpose, benefits, and limitations of genomic/transcriptomic testing, and that, unless indicated otherwise below, you consent to a) the release of your specimens and clinical information to BostonGene for the BostonGene Tumor Portrait™ Test, b) the retention and use of your de-identified specimens, test results, and clinical information for as long as deemed useful for research and development purposes, which may be indefinite, c) to receive secondary findings, and d) future contact regarding ongoing research.

- <sup>3</sup> CHECK THIS BOX IF YOU **DO NOT CONSENT** TO THE RESEARCH AND DEVELOPMENT USE OF YOUR DE-IDENTIFIED SAMPLES AND DATA AS DESCRIBED IN THE RELEVANT SECTION ABOVE.
- <sup>4</sup> CHECK THIS BOX IF YOU **DO NOT CONSENT** TO RECEIVE SECONDARY FINDINGS THAT ARE NOT RELATED TO CANCER.
- <sup>5</sup> CHECK THIS BOX IF YOU **DO NOT CONSENT** TO RECEIVE FUTURE CONTACT REGARDING ONGOING RESEARCH.

PATIENT SIGNATURE	PRINTED NAME	DATE (MM/DD/YYYY)
-------------------	--------------	-------------------

\*MINNESOTA RESIDENTS ONLY: BY SIGNING ABOVE YOU CONSENT TO THE RETENTION OF YOUR DE-IDENTIFIED SAMPLES, DNA/RNA AND GENETIC/CLINICAL INFORMATION FOR UP TO 30 YEARS UNLESS YOU INDICATE OTHERWISE ABOVE.

ALASKA, DELAWARE, NEVADA, NEW MEXICO, AND NEW YORK RESIDENTS ONLY: BY SIGNING ABOVE YOU CONSENT TO THE RETENTION OF YOUR DE-IDENTIFIED SAMPLES, DNA/RNA AND GENETIC/CLINICAL INFORMATION UNLESS YOU INDICATE OTHERWISE ABOVE IN WHICH CASE YOUR SAMPLES WILL BE DESTROYED WITHIN 60 DAYS AFTER COLLECTION OR UPON COMPLETION OF THE GENETIC TESTS FOR WHICH THEY WERE COLLECTED. BY SIGNING ABOVE YOU ALSO CONSENT TO FUTURE CONTACT UNLESS YOU INDICATE OTHERWISE ABOVE.